Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | MPL | P40238 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12739842 | 0.97 | FFAR4 (0.35) | RARBS1PR1FFAR4MAOAMAOB | |
| SCHEMBL12739896 | 0.96 | RARB (0.39) | RARBS1PR1FFAR4RARARARG | |
| SCHEMBL12739893 | 0.93 | FFAR4 (0.37) | RARBS1PR1FFAR4SPHK1MPL | |
| SCHEMBL12739986 | 0.93 | RARB (0.37) | RARBS1PR1FFAR4RARARARG | |
| SCHEMBL12739839 | 0.91 | FFAR4 (0.34) | RARBS1PR1FFAR4MPL | |
| SCHEMBL12739841 | 0.91 | FFAR4 (0.35) | RARBFFAR4MAOAMAOBMPL | |
| SCHEMBL12740034 | 0.90 | RARB (0.39) | RARBS1PR1FFAR4RARARARG | |
| SCHEMBL12739984 | 0.90 | FFAR4 (0.36) | RARBS1PR1FFAR4MPL | |
| SCHEMBL12735067 | 0.90 | SPHK1 (0.34) | RARBFFAR4MAOAMAOBSPHK1 | |
| SCHEMBL12739801 | 0.90 | SPHK1 (0.34) | RARBFFAR4MAOAMAOBSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | RARB 2705/4885S1PR1 1190/4885FFAR4 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.